Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases.
D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy / Q000401:mortality / Q000556:secondary*; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood*; D000726:Androgen Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000097:blood / Q000188:drug therapy / Q000401:mortality / Q000556:secondary*; D002118:Calcium / Q000652:urine; D003094:Collagen / Q000097:blood*; D024042:Collagen Type I; D003404:Creatinine / Q000652:urine; D019008:Drug Resistance, Neoplasm; D005500:Follow-Up Studies; D006801:Humans; D007558:Italy / Q000453:epidemiology; D017567:Karnofsky Performance Status; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000097:blood*; D010748:Phosphopeptides / Q000097:blood*; D011347:Procollagen / Q000097:blood*; D016016:Proportional Hazards Models; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000401:mortality; D016019:Survival Analysis; D013997:Time Factors
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D024042:Collagen Type I; C062121:N-propeptide type I collagen; D010455:Peptides; D010748:Phosphopeptides; D011347:Procollagen; C052929:collagen type I trimeric cross-linked peptide; D003094:Collagen; D003404:Creatinine; D000469:Alkaline Phosphatase; D002118:Calcium